Skip to content
drillr.ai

PHVS

Pharvaris N.V.

NASDAQ · NLHealthcareBiotechnology
$33.55-3.98%

Price as of Jul 20, 2026

PHVS news

Pharvaris N.V. news

A server-rendered, paginated timeline of the latest available company news.

  1. Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

    * If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks * NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profile * PDUFA action date set for April 23, 2027 ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (https://www.globenewswire.com/Tracker?data=6CpSfpCo16MJBUuFa7R2rRlFfTy3AThnKyHGAkHYnBUkPYsW8seqrhoQOhR

    Globe Newswire ·

  2. Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

    * Results from prespecified assessment of End of Progression™ in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint detailed in an oral presentation * Evidence on the cardiovascular safety profile of deucrictibant in clinical studies to date presented ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (https://www.globenewswire.com/Tracker?data=sZx5ActIGL_VWwZbGJj7SO5zqJRtGf2vvIRw9YfdeqWzHEjH0_XgnwHeYN9LsBrQAnoZ_DVzvH1XPMon1E90Y_vGgDm6MXOpSMyZTKRbGwbWfjJ3

    Globe Newswire ·

  3. Pharvaris Announces Annual General Meeting of Shareholders

    ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (https://www.globenewswire.com/Tracker?data=H6zwhvr5NSIrBYw6btXLX2xrsbKYn8_qO25P60HTGOY-hlrDOGDZQKOkloOBl116TMLAamyPhyFzqEL6FJR6Tg==) (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today ann

    Globe Newswire ·

  4. Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

    ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=) (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living

    Globe Newswire ·

  5. Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (“HAE”) and acquired angioedema due to C1 inhibitor deficiency (“AAE-C1INH”), today announced the closing of its previously announced underwritten offering of 4,455,863 ordinary shares (which includes

    Globe Newswire ·

  6. Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

    ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (https://www.globenewswire.com/Tracker?data=6Z-xvZ5cSjSzN4MRb7H1XlgmGASg6RajS1BVMCnWNYKik-kuSzDRaasYEu9mWoemevpSMCr7bR8AaACus2ut1Q==) (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presente

    Globe Newswire ·

  7. Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    * Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026 * Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026 * Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks * Cash and cash equivalents of €292 million as of December 31, 2025 ZUG, Switzerland, Apri

    Globe Newswire ·

  8. Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology

    * Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAE ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (https://www.globenewswire.com/Tracker?data=tCrM0HjLiGqebw91VaAfFyF8jJnAoihy1v6AdJ8bIIF3Ry5JTErMHHQeXB5MaA8bEYRH9x1ULbBaSivLAIokqw==) (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those

    Globe Newswire ·

  9. Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

    * Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAPIDe-3 endpoints ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (https://www.globenewswire.com/Tracker?data=8Dt544f3n5hCEAS00t4WCXd1eMSO1caJcn4suJVNlcwhlr9uA-ZFNoJj-QZGBrUQOjxfMJwS79zTiocrERbI_A==) (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradyki

    Globe Newswire ·

  10. Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026

    * RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and confirming its potentially differentiated profile for the treatment of HAE attacks * Final CHAPTER-1 data provide further evidence on long-term safety and efficacy of deucrictibant for the prevention of HAE attacks; single-dose, sustained therapeutic exposure with deucrictibant

    Globe Newswire ·